(Q44238352)

1 December 2017

"Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors (English)

1 reference

1 December 2017

Stanley M Lemon

1

1 reference

1 December 2017

Minkyung Yi

series ordinal

2

1 reference

1 December 2017

Kui Li

series ordinal

3

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

1 December 2017

1 reference

1 December 2017

41

1 reference

1 December 2017

671-674

1 reference

1 December 2017

3

1 reference

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 December 2017

1 reference

7 January 2021

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

7 January 2021

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

7 January 2021

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

1 reference

7 January 2021

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

1 reference

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

7 January 2021

Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis

1 reference

7 January 2021

Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons

1 reference

7 January 2021

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

1 reference

7 January 2021

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

1 reference

7 January 2021

Peptide-based inhibitors of the hepatitis C virus serine protease

1 reference

7 January 2021

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

1 reference

7 January 2021

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

1 reference

7 January 2021

Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis

1 reference

7 January 2021

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

1 reference

7 January 2021

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

1 reference

7 January 2021

Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors

1 reference

7 January 2021

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

1 reference

7 January 2021

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

7 January 2021

Preventing and managing resistance in the clinical setting

1 reference

7 January 2021

Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20610

1 reference

1 December 2017

1 reference